Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [03/16/2020 10:10 PDT] Protalix BioTherapeutics, Inc. (NYSE:PLX), Down By 100.00% ($2.39) From $2.390 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [03/13/2020 07:50 PDT] PLX Expected to Trade Down After Bearish Patterns Develop
• [02/21/2020 11:30 PST] PLX Expected to Trade Up After Bullish Patterns Develop
• [02/20/2020 10:10 PST] Protalix BioTherapeutics, Inc. (NYSE:PLX), Up By 100.00% ($3.29) From $3.290 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/18/2020 07:17 PST] PLX Expected to Trade Up After Bullish Patterns Develop